BioStock Studio: Cereno Scientific’s CEO comments on the third quarter
Spotlight-listed Cereno Scientific recently released its third quarter report. During the period, the company reached several milestones, the most significant being when FDA accepted Cereno’s IND application for the phase II trial with drug candidate CS1. CEO Sten R Sörensen elaborated in BioStock’s studio interview.
Watch the interview, in Swedish, with Cereno Scientific's CEO Sten R Sörensen at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/